264 related articles for article (PubMed ID: 26618342)
1. Management of Chronic Lymphocytic Leukemia in the Elderly.
Barrientos JC
Cancer Control; 2015 Oct; 22(4 Suppl):17-23. PubMed ID: 26618342
[TBL] [Abstract][Full Text] [Related]
2. Beyond detectable minimal residual disease in chronic lymphocytic leukemia.
Hillmen P
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S23-8. PubMed ID: 16720200
[TBL] [Abstract][Full Text] [Related]
3. Chronic lymphocytic leukemia: current and emerging treatment approaches.
Kay NE; Rai KR; O'Brien S
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
[TBL] [Abstract][Full Text] [Related]
4. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on chronic lymphocytic leukemia: a Pharma Matters report.
D'Souza P; Walker G
Drugs Today (Barc); 2014 Jul; 50(7):485-501. PubMed ID: 25101331
[TBL] [Abstract][Full Text] [Related]
6. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
Seiter K; Mamorska-Dyga A
Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852
[TBL] [Abstract][Full Text] [Related]
7. Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents.
Maly J; Blachly JS
Curr Hematol Malig Rep; 2016 Feb; 11(1):52-60. PubMed ID: 26893063
[TBL] [Abstract][Full Text] [Related]
8. Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review.
Farooqui AA; Ashraf A; Farooq TB; Anjum A; Rehman SU; Akbar A; Kanate A; Dean R; Ahmed MQ; Tariq MJ; Nabeel S; Faisal MS; Anwer F
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e414-e426. PubMed ID: 32291235
[TBL] [Abstract][Full Text] [Related]
9. Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs.
Smolewski P; Robak T
Acta Haematol; 2021; 144(4):365-379. PubMed ID: 33238270
[TBL] [Abstract][Full Text] [Related]
10. Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist.
Pinilla-Ibarz J; Emole J
Cancer Control; 2015 Oct; 22(4 Suppl):7-16. PubMed ID: 26618341
[TBL] [Abstract][Full Text] [Related]
11. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
Montillo M; Schinkoethe T; Elter T
Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
[TBL] [Abstract][Full Text] [Related]
12. Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial.
Molica S
Expert Rev Anticancer Ther; 2015 Jan; 15(1):9-15. PubMed ID: 25479582
[TBL] [Abstract][Full Text] [Related]
13. Standard of care and novel treatments for chronic lymphocytic leukemia.
Seung AH
Am J Health Syst Pharm; 2010 Nov; 67(21):1813-24. PubMed ID: 20966144
[TBL] [Abstract][Full Text] [Related]
14. Incorporating targeted agents into future therapy of chronic lymphocytic leukemia.
Pallasch CP; Hallek M
Semin Hematol; 2014 Jul; 51(3):235-48. PubMed ID: 25048787
[TBL] [Abstract][Full Text] [Related]
15. Clinical roundtable monograph: unmet needs in the treatment of chronic lymphocytic leukemia: integrating a targeted approach.
O'Brien SM; Furman RR; Byrd JC; Smith A
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 3):1-13. PubMed ID: 24870382
[TBL] [Abstract][Full Text] [Related]
16. [Chronic lymphocytic leukemia: current standards and novel approaches].
Tausch E; Stilgenbauer S
Internist (Berl); 2014 Dec; 55(12):1400, 1402-4, 1406-9. PubMed ID: 25392275
[TBL] [Abstract][Full Text] [Related]
17. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
19. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
[TBL] [Abstract][Full Text] [Related]
20. Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Varma G; Johnson TP; Advani RH
Clin Adv Hematol Oncol; 2016 Jul; 14(7):543-54. PubMed ID: 27379948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
